MediWound announces results from NexoBrid Expanded Access Protocol

MediWound announced the positive results of the NEXT-an Expanded Access Protocol. NEXT, initiated in 2019, aimed to ensure the continuous availability of NexoBrid(R) in burn centers until its commercialization. This program successfully maintained physician expertise, provided burn victims with ongoing access to this life-saving treatment, and facilitated the accumulation of real-world safety and clinical data for NexoBrid. Key Results of the NEXT Protocol Include: Efficacy: 94.9% of adults and 100% of children achieved complete debridement. Only 4.2% of adults required surgical excision for eschar removal after NexoBrid treatment, and none in the pediatric group. The mean percent of wound area surgically excised for adults was 3.6%, and 0% for children. The time to complete eschar removal was less than one day for both adults and children. Healing and Hospitalization: The median time to wound closure was 22 days for adults and 28 days for children. The median time of hospitalization duration was 10 days for adults and 10 days for children. Safety: The safety data was consistent with the established safety profile of NexoBrid, and no new safety concerns were identified by the Data Safety and Monitoring Board. Benefit-Risk Ratio: The overall benefit-to-risk ratio of NexoBrid treatment remains favorable.